Servier 1

Drug Profile

Servier 1

Alternative Names: BCL-201; S 055746; S-55746; Servier-1

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier; Vernalis
  • Developer Novartis Pharmaceuticals Corporation; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcl-X protein inhibitors; MCL1 protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma

Most Recent Events

  • 22 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndrome presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 22 Jun 2017 Preliminary adverse events data from a phase I trial in Chronic Lymphocytic Leukaemia presented at the 22nd Congress of the European Haematology Association (EHA - 2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top